Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Y-box factor YB1 controls p53 apoptotic function.

Craig Homer1, Deborah A Knight, Lynne Hananeia

  • 1Pathology Department, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, Otago 9001, New Zealand.

Oncogene
|September 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Breast Cancer Detection in Higher Risk Women: A Multi-Modality Imaging Evaluation in a Private Screening Clinic.

Journal of medical imaging and radiation oncology·2026
Same author

Δ133p53 isoform enhances TLR4 function to promote tumor growth.

Carcinogenesis·2025
Same author

Iron content of glioblastoma tumours and role of ferrous iron in the hypoxic response <i>in vitro</i>.

Frontiers in oncology·2025
Same author

Analysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study.

Cancers·2024
Same author

Combining TP53 mutation and isoform has the potential to improve clinical practice.

Pathology·2024
Same author

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

The Journal of clinical investigation·2023

Nuclear YB1 protein regulates the p53 tumor suppressor, inhibiting cell death pathways but not cell cycle arrest. This interaction may explain YB1

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Nuclear localization of Y-box-binding protein 1 (YB1) correlates with drug resistance and poor tumor prognosis.
  • YB1 is known to interact with the p53 tumor suppressor protein.

Purpose of the Study:

  • To investigate the functional relationship between YB1 and p53.
  • To elucidate how YB1 influences p53 activity in cancer-related pathways.

Main Methods:

  • Investigated YB1/p53 interactions in cellular models.
  • Assessed the impact of nuclear YB1 on p53-mediated transactivation and cell death.
  • Analyzed protein level changes (e.g., Bax) following p53 activation in the presence of nuclear YB1.

Main Results:

Related Experiment Videos

  • Transcriptionally active p53 is necessary for YB1 to localize in the nucleus.
  • Nuclear YB1 inhibits p53-induced cell death and the transactivation of pro-death genes.
  • Nuclear YB1 does not impede p53's transactivation of CDKN1A (p21) or MDM2.
  • Nuclear YB1 is linked to a failure in Bax protein upregulation after p53 activation in stressed mammary epithelial cells.

Conclusions:

  • Nuclear YB1 selectively modulates p53 activity, specifically hindering apoptosis.
  • This selective alteration of p53 function by nuclear YB1 offers a potential mechanism for its association with drug resistance and poor tumor prognosis.